Zhejiang Garden Biopharmaceutical Co.,Ltd.(300401.SZ)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 659 | 1,117 | 1,418 | 1,095 | 1,243 | 1,237 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 263 | 484 | 384 | 192 | 309 | 305 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Zhejiang Garden Biopharmaceutical Co.,Ltd. operates as a food additive and pharmaceutical manufacturing industry in China. The company provides lanolin cholesterol, vitamin A and AD3 particles, vitamin D3, 25-hydroxyvitamin D3, chemical drugs and Chinese patent medicines. It offers cholesterol; feed grade vitamin D3, refined lanolin; food additives compound nutrient fortifier SDS, CO, and MO; cholecalciferol; feed additive - vitamin D3 particles and oil; VD3 resin oil; 25 hydroxyvitamin D3 progen and powder; 25 hydroxyvitamin D3; anhydrous lanolin; wood oil; wool wax; low chroma pure fat; lanolin alcohol; isopropyl lanolate; lanolinic acid; high acid fat; wood acid biofuel/wood alcohol biofuel; and rodenticide made from Vitamin D3. Zhejiang Garden Biopharmaceutical Co.,Ltd. was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmaceutical Co.,Ltd. in April 2023. Zhejiang Garden Biopharmaceutical Co.,Ltd. was founded in 2000 and is based in Dongyang, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Zhejiang Garden Biopharmaceutical Co.,Ltd. (300401.SZ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Zhejiang Garden Biopharmaceutical Co.,Ltd. operates as a food additive and pharmaceutical manufacturing industry in China. The company provides lanolin cholesterol, vitamin A and AD3 particles, vitamin D3, 25-hydroxyvitamin D3, chemical drugs and Chinese patent medicines. It offers cholesterol; feed grade vitamin D3, refined lanolin; food additives compound nutrient fortifier SDS, CO, and MO; cholecalciferol; feed additive - vitamin D3 particles and oil; VD3 resin oil; 25 hydroxyvitamin D3 progen and powder; 25 hydroxyvitamin D3; anhydrous lanolin; wood oil; wool wax; low chroma pure fat; lanolin alcohol; isopropyl lanolate; lanolinic acid; high acid fat; wood acid biofuel/wood alcohol biofuel; and rodenticide made from Vitamin D3. Zhejiang Garden Biopharmaceutical Co.,Ltd. was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmaceutical Co.,Ltd. in April 2023. Zhejiang Garden Biopharmaceutical Co.,Ltd. was founded in 2000 and is based in Dongyang, China.
